Available online on 15.04.2026 at http://ajprd.com

Asian Journal of Pharmaceutical Research and Development

Open Access to Pharmaceutical and Medical Research



Open Access

Review Article

Pharmacovigilance in Clinical Trails

Shelke Nikita S., Shelke Harshal B., Sathe Dipti B., Sangale Vaibhavi S.

Pravara Rural Education Society College of Pharmacy Chincholi, Nashik 422102, Maharashtra, India.

A B S T R A C T

An essential component of the entire drug development process is pharm acovigilance. Pharmacovigilance is the ongoing observation, assessment, and interpretation of possible side effects or other problems pertaining to medications. By weighing the advantages and disadvantages of particular medications, this promotes patient safety. Pharmacovigilance has been more effective with the use of information technology, allowing for improved monitoring and clinical safety procedures. It is essential to ensuring the cost-effectiveness, safety, and efficacy of medications over their entire lifecycle, from research to postmarketing monitoring. ICH GCP, USFDA standards, and other regulatory g uidelines regulate the clinical trial procedure.The evidence underpinning for regulatory judgments about safe and effective medications is provided by clinical studies. A crucial part of every stage of the drug development life cycle is safety evaluation A crucial part of every stage of the drug development life cycle is safety evaluation. The ultimate objective of pharmacovigilance in clinical trials is to monitor and evaluate the test product's safety profile.

Keyword: Pharmacovigilance, Post marketing monitoring, Clinical Trails

A R T I C L E I N F O: Received 20 Nov. 2025; Review Complete 28 Dec. 2025; Accepted 27 March 2026; Available online 15 April. 2026

Cite this article as:

Shelke N S, Shelke H B, Sathe D B, Sangale V S, Pharmacovigilance In Clinical Trails, Asian Journal of Pharmaceutical Research and Development. 2026; 14(2):46-50, DOI: http://dx.doi.org/10.22270/ajprd.v14i2.1719

*Address for Correspondence:

Shelke Nikita S, Pravara Rural Education Society College Of Pharmacy (D and B pharm) Chincholi,Nashik 422102, Maharashtra, India.

INTRODUCTION

The name “pharmacovigilance” comes from the Latin word “vigilare,” which means “watching over,” and the Greek word “pharmacon,” which means “medication” or “medicinal.” Pharmacovigilance is unquestionably a crucial step in the entire drug development process. By weighing the advantages and disadvantages of specific medications, this guarantees patient safety. With the use of information technology, improved clinical safety procedures, and more efficient monitoring, pharmacovigilance has significantly increased. It is essential to guaranteeing the cost-effectiveness,safety, and efficacy of medications at every stage of their life cycle, from discovery to post-marketing monitoring. The relevant regulatory guidelines (ICH GCP, USFDA guidelines, etc.) control the clinical trial process.The evidence-based foundation for regulatory approvals of safe and effective medications is provided by clinical trials. 6 GCP defines the “standard for conducting, performance, planning, monitoring, recording, auditing, analysis and reporting of clinical trials that provides assurance that the informationand results reported are credible and accurate which rights, integrity and confidentiality of subjects of trial are safeguarded” .7.In every stage of the drug development life cycle, safety evaluation might be a crucial component. Observing and evaluating the safety profile of the experimental product is the main goal of pharmacovigilance during clinical trials [1].

WHAT IS PHARMACOVIGILANCE:-

Pharmacovigilance (PV) is defined by the World Health Organization (WHO) as “a pharmacological science which deals with safety of drugs and activity Which concern to assess, detect, comprehend and Prevent harmful effects or the drug-related issue.” By creating a mechanism to collect, evaluate, and distribute drug safety data, PV seeks to improve patient safety with regard to medication use. Monitoring approved medications and investigational medicinal products (IMPs) is one of PV’s tasks. Its goals are to: Identify adverse effects that have not yet been identified. Acknowledge variations in the known negative consequences’ severity. Assess the risks and benefits ofIdentify adverse effects that have not yet been identified. Acknowledge variations in the known negative consequences’ severity. Assess the risks and benefits of a

medication to decide whether safetymeasures should be implemented. Make that the information in patient information leaflets (PILs) is up to date and that the data provided to patients and healthcare providers is accurate.[2]

Thalidomide Tragedy (1950s–1960s): Thousands of babies were born with severe birth deformities as a result of the drug, which was initially recommended as a sedative and antiemetic. The need for systemic medication safety monitoring was highlighted by this disaster. The fallout raised awareness of the possible harm that medications, particularly during pregnancy, could cause

1. WHO Program Formation (1968): The International Drug Monitoring Program was created by WHO in 1968 as a reaction to the thalidomide disaster. By encouraging cooperation in the gathering and analysis of data on adverse drug reactions (ADRs), this program established the framework for aninternational network of pharmacovigilance centers
2. FDA and AERS (1970s): The FDA initiated the Adverse Event reporting system (AERs) in1970s. AERs become a pivotal tool for collecting, managing, and analyzing data on adverse events associated with drugs, enabling the FDA to monitor and regulate drug safety in United States [3]

HISTORY

1. The 1950s–1960s Thalidomide Tragedy: Originally prescribed as a sedative and antiemetic, thalidomide caused severe birth
2. Abnormalities in thousands of infants. The catastrophe brought to light the necessity of systematic drug safety monitoring. As a result, people were more aware of the possible harm that medications could cause, especially during pregnancy
3. WHO Program Formation (1968): The International Drug Monitoring Program was founded by WHO in 1968 as a result of the thalidomide incident. By fostering collaboration in the collection and assessment of data on adverse drug reactions (ADRs), the Program served as the foundation for a global network of pharmacovigilance centers.[2]
4. FDA and AERS (1970s): In the 1970s, the FDA launched the Adverse Event Reporting System (AER). The FDA was able to monitor and regulate drug safety in the US thanks to AERs, which became a vital tool for collecting, managing, and evaluating data on medication adverse occurrences [3].

Pharmacological in needed pharmacological examine:-

side effects that are not related to a medication's effectiveness. That is, it establishes what adverse effects are acceptable based on how well t hey treat a condition. the patients' danger. incomplete data gathered when the drug was being premarketed. Both in developing and develo ping nations, ADRS is the primary cause of disease and mortality. ADRs ranked as the fourth or fifth most common cause of mortality in the US in 1994. 5700 deaths in the UK are thought to be related to ADRs annually, according to some estimates. 30–70% of ADRs could be avoided. Patients' medical expenses rise as a result, and their trust in the healthcare system declines.[4]

REASON

Reason 1: Insufficient safety evidence from clinical trials and humanitarian concerns Animal studies are conducted in phases 1-3 before being approved for sale.

Reason 2: Drugs are meant to prolong life. While dying from an illness is occasionally unavoidable, dying from a medicine is not desirable.

Reason 3: ADRs are more expensive nationwide than the actual cost of the medications.

Reason 4: Encouraging adherence to rules and responsible drug usage.

Reason 5: Preservation of public trust. Reason 6: It is unethical to know anything that could hurt someone else yet not tell them. [5]

PRINCIPLES OF CLINICAL TRIAL/RESEARCH RAW CONCLUSION

Although clinical trials can take many different forms, they are often classified as analytical, observational, or experimental studies. Additional areas under which clinical investigations might be divided include medication trials and targeted and non-targeted data collection. Clinical investigations can be conducted in both forward and backward directions. It could also be a cohort or case-control study. Clinical studies can be started in order to detect, treat, avoid, observe, or diagnose a medical issue. Among the different kinds of clinical research, cross-sectional studies and observational studies are the most common. The goals of this kind of research are to examine the existence or lack of a sickness or ailment, possible risk factors, and the incidence and prevalence rates of a population.Depending on the kind of intervention, clinical investigations can be classified as either therapeutic or non-therapeutic. Therapeutic clinical tests employ a medication that may be advantageous to the participants. However, in a non-therapeutic clinical trial, the subject is not impacted by the medication. For potential future development, the non-therapeutic tests offer further details on the medication. Different words used in clinical investigations are illustrated in the table [6]

PHARMACOVIGLANCE IN CLINICAL TRIALS

Pharmacovigilance might involve continuous monitoring and assessment of every adverse event during the drug development process to ensure participant safety and benefit is continuously assessed. Clinical studies under careful observation provide the majority of the safety data taken into account prior to marketing approval. The exact regulatory rules (such as ICH GCP and USFDA guidelines) govern the clinical test procedure. [7]

Pharmacovigilance, often known as drug safety, is the art of comprehending a drug's adverse effects and determining whether the benefit will outweigh the danger. This entails detecting side effects during the clinical trial and post-

marketing stages, keeping an eye on and modifying the risk-benefit ratio in light of pertinent observations, preventing or minimizing side effects, and—above all—quickly and consistently informing the relevant international regulatory bodies of such observations.[8]

PHARMACOVIGLANCES OUTSIDE OF CLINICAL RESEARCH

Study restrictions restrict the pharmacovigilance data derived from clinical research. Clinical study pv data is unable to detect:

1. Potential medication interactions
2. Long-term danger
3. Dangers associated with increased dosages
4. Risks associated with drug usage and misuse

Therefore, it is necessary to update the potential dangers of medications through continuous patient and healthcare provider feedback. In order to keep an eye on the ”real world,” the pharmaceutical company can support post-marketing medicine safety Monitoring, a particular kind of Phase IV study. Product safety and effectiveness, as preapproval trials are unable to predict any potential adverse pharmacological effects. Other approaches, such as drug registries, electronic health records, and spontaneous reporting systems, can be used.[9]

Clinical Research

Clinical trials are carried out on volunteers to provide conclusive answers regarding the safety and effectiveness of medications, vaccines, other treatment modalities, or novel approaches to using already-existing therapies. Clinical trials are conducted according to a particular study protocol created by the producer, investigator.The developer must incomplete researcherInvestigational New Drug Process (IND) before beginning cli nical investigations. They will accomplish this while planning the clinica l study, taking into account their goals for each of the several clinical re search phases. Before starting a clinical trial, researchers review the inf ormation that is already known regarding the medicine to generate stu dy questions andobjectives.[10]

1. Selection criteria for participants
2. The number of participants
3. The length of the research
4. Dose and dose type administration technique
5. Parameter measurement
6. Data gathering and evaluation.

Clinical studies in phase zero First-in-human (FIH) investigations carried out in accordance with FDA regulations are referred to as phase 0. Phase 0 trials, often known as human microbe studies, include giving single subtherapeutic doses to 10–15 volunteers in an attempt to gather pharmacokinetic data or assist in imaging particular targets without the use of pharmacological activities.

Phase 0 investigations are carried out by pharmaceutical companies to determine which of their drug candidates have the best human pharmacokinetic characteristics.[11]

Phase 1: Dosage and safety The first medication investigations with fewer healthy human participants are called phase I trials. Typically, 20 to 80 healthy volunteers with the illness or condition participate in phase 1. Patients are often only employed when a medication’s mode of action shows that healthy individuals Will be incapable of enduring it. However, if a new medication is suggested for use in those persons with that type of diabetes, researchers perform Phase 1 trials on them. Phase 1 studies gather information on the pharmacodynamics of the human body while being closely observed. Researchers modify the dosing schedule based on data from animal tests to determine what dosage of a medicine is acceptable to the body and what its immediate negative effects are. Scientists learn more about the mode of action, adverse effects linked to increasing dosage, and efficacy when a Phase 1 experiment is completed. This is essential to the design of the Phase 2 study. Nearly 70% of medications advance to the following stage.[12]

3 Phase 2: Side effects and effectiveness Phase II trials, which are intended to assess the drug’s effectiveness and ensure that it passes Phase I safety testing, contain large patient groups (hundreds). To ascertain whether the medication will be therapeutic or not, these investigations are insufficient. Phase 2 studies can provide researchers with more safety information. These data are used by researchers to create new

Phase 3 study protocols, hone their research topics, and create research designs.Roughly one-third of medications advance to the next stage. Finding therapeutic dosages for the large Phase III trials is the primary contribution of Phase II clinical research.[13]

4. Phase 3: 9 Keeping an eye on medication side effects and effectiveness Researchers create phase 3 studies to demonstrate whether a product offers a certain action advantage to a particular person. These 300–3,000 person examinations are now referred to as paradigm studies. Phase 3 trials provide the majority of the safety information. It’s possible that less frequent adverse effects were missed in the previous trial. However, phase 3 trials are more likely to discover rare or delayed side effects since they are longer and involve more volunteers. About 25–30% of medications advance to the following phase of clinical trials.If a drug manufacturer provides evidence from preclinical, clinical, and prior testing demonstrating that the medicine is safe and effective for its intended use, the industry may submit a petition to sell the drug. The FDA review panel decides whether to approve or deny a medicine after carefully considering all of the material that has been submitted.[14]

MONITORING OF QUANTIFYING ADRS

Numerous techniques have been used to quantify the rate of ADRs. These include meta-analysis, ecological research, medical claims database analysis, and medication event monitoring, which records all drug-related events that take

place while patients take specific observed prescriptions. [15]

A variety of approaches are required since no single approach can fully satisfy all of the requirements for uncommon ADRs

This reporting mechanism has significantly improved the effectiveness of post-marketing drug safety monitoring and is widely regarded as the cornerstone of pharmacovigilance. [17–18]

Since no single strategy may best satisfy every requirement for effective ADR information collecting, a variety of approaches are required. [13] Spontaneous reporting is the most popular technique in pharmacovigilance, and it works well for creating alerts for novel or uncommon ADRs. [18]

ADVERSE DRUG REACTIONS

An unpleasant and unexpected reaction that happens at dosages usually used in humans for illness prevention, diagnosis, or treatment, or for altering physiological function. Pharmacovigilance's job is to determine which side effects go beyond a medication's limit of effectiveness. That is, evaluating how well a medication cures an illness and determining whether side effects are worth a patient's risk. For instance, chemotherapy has several quite dangerous side effects, yet they are tolerable when cancer is present and may be fatal. The likelihood that a patient will recover However, if a drug used to treat a headache had the same adverse effects, the patient would be considered to be at too great of a risk, and the benefit would not be considered significant enough to outweigh the risk. [19]

ADVERSE EVENTS

ICH E6: Any unintended medical event that occurs in a patient or clinical study participant receiving a pharmaceutical product and is unrelated to the treatment is considered an adverse event.[20]An unintended and unpleasant reaction (such as an unexpected laboratory result), symptom, or illness linked to the use of a pharmaceutical (investigational) product can also be referred to as an adverse event. [21] Timeline of reportingThe cornerstone of pharmacovigilance is prompt reporting of adverse occurrences. Reporting deadlines are set by regulatory agencies such as the FDA and EMA, with expedited requirements for serious and unexpected events. Timelines like these aid in possible safety. Early resolution of issues is necessary to reduce patient hazards. [22]

DATA COLLECTING AND MANAGEMENT

Pharmacovigilance for clinical trials requires the monitoring and gathering of data. There are robust processes and procedures in place to ensure that safety data is collected reliably and consistently. This could involve using electronic data capture (EDC) tools or preformatted case report forms (CRFs). Data entry, adverse event classification, and quality control procedures are all included in data management to guarantee the accuracy and dependability of the information gathered.[23]

FUTURE DIRECTIONS

Proactive pharmacovigilance and real-time surveillance: Technology can help with proactive detection and management of safety signals by enabling real-time monitoring of safety data. Throughout clinical trials, safety vigilance can be improved by utilizing real-world evidence, wearable technology, and ongoing patient data monitoring. Integration of machine learning and artificial intelligence: More integration of machine learning (ML) and artificial intelligence (AI) techniques can help with risk prediction, signal recognition, and automated adverse event detection. The efficacy and precision of pharmacovigilance initiatives are increased by AI algorithms' ability to process massive data sets, find trends, and generate real-time safety .

CONCLUSION

Pharmacovigilance is a key part of clinical trials and overall drug development, with the patient's safety being the primary priority. It guarantees a positive risk-benefit ratio for the course of a drug's lifespan by continuously monitoring, assessing, and reporting adverse drug responses and incidents. Post-marketing surveillance and real-world monitoring become equally critical because clinical trials, albeit providing vital safety information, are often characterized by limitations. Pharmacovigilance is evolving into a more precise and proactive science thanks to technological breakthroughs like artificial intelligence, electronic health records, and real-time monitoring tools. In the end, effective pharmacovigilance enhances the safety and effectiveness of drugs for the populations they are meant to treat, safeguards public health, and builds confidence in healthcare institutions

REFERENCCES

1. Kanala K, Hwisa NT, Chandu BR, Assaleh FH, Mukkanti K, Katakam P, Challa BS. Simultaneous quantification of mesalamine and its metabolite N-acetyl mesalamine in human plasma by LC-MS/MS and its application to a bioequivalence study. Br J Pharm Res. 2014;4(13):1568. Available from: https://www.ijpsjournal.com
2. De Carvalho PM, et al. Brazilian regulation in pharmacovigilance: a review. Pharmaceut Reg Affairs. 2016;5:164.
3. Härmark LV. Web-based intensive monitoring: a patient-based pharmacovigilance tool. EPRA Journal. [Internet]. Available from: https://doi.org/10.36713/epra15259
4. Muhannad RS, Arwa YA, Omer QBA, Ramdan ME, Kurmanji JM. Psychometric evaluation of physicians toward pharmacovigilance practice in Iraq. J Pharmacovigilance. 2016;4(214):2–3.
5. Singh S, Prakash J, Goyal N, Tomar R, Chaudhary R. Pharmacovigilance. World J Pharm Pharm Sci. 2015;4(6):271–273.
6. Kandi V, Vadakedath S. Clinical research: an overview of study types, designs, and implications in the public health perspective. Am J Clin Med Res. 2021;9(2):36–42.
7. Kengar MD, Patole KK, Ade AK, Kumbhar SM, Patil CD, Ganjave AR. Introduction to pharmacovigilance and monitoring. Asian J Pharm Res. 2019;9(2):116–122.
8. Mane SR, Bais SK, Gavade SK. Novel approaches in pharmacovigilance. Int J Pharm Clin Res. 2024;2(1):1414–142.
9. Mazzitello C, et al. Pharmacovigilance in Italy: an overview. J Pharmacol Chemother. 2013;4(1 Suppl):S20–S28.
10. Fitzpatrick S. The clinical trial protocol. Institute of Clinical Research; 2005.

11. Kinders R, et al. Phase 0 clinical trials in cancer drug development: from FDA guidance to clinical practice. Mol Interv. 2007;7(6):325.
12. DiMasi JA. Risks in new drug development: approval success rates for investigational drugs. Clin Pharmacol Ther. 2001;69(5):297–300.
13. Friedhoff LT. New drugs: an insider's guide to the FDA's new drug approval process for scientists, investors, and patients. PSPG Publishing; 2009.
14. Gibbons RD. Post-approval drug safety surveillance. Annu Rev Public Health. 2010;31(1):419–437.
15. Pirmohamed M, James S, Meakin S, Green C, Scott A. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18,820 patients. BMJ. 2004;329(12):15–19.
16. Fletcher AP. Spontaneous adverse drug reaction reporting vs event monitoring: a comparison. J R Soc Med. 1991;84(6):341–344.
17. Alvarez-Requejo A, Carvajal A, Begaud B, Moride Y, Vega T, Martin Arias LH. Under-reporting of adverse drug reactions: estimate based on a spontaneous reporting scheme and a sentinel system. Eur J Clin Pharmacol. 1998;54(20):483–488.
18. Pirmohamed M, Breckenridge A, Kitteringham NR, Park BK. Adverse drug reactions. BMJ. 1998;316(23):1295–1298.
19. Hama R. The mechanisms of adverse reactions to oseltamivir: part II. delayed type reactions. Clin Microbiol. 2015;4:224.
20. Klepper MJ. The periodic safety update report as a pharmacovigilance tool. Drug Saf. 2004;27:569–578.
21. Kowalski CJ, Mrdjenovich AJ. Pharmacovigilance observed: why watchful waiting will work. J Clin Diagn Res. 2015;3:114.
22. Pisipati SV, Pathapati H, Bhukya G, Nuthakki S, Chandu B, Nama S, Adeps R. Lycopene: redress for prostate cancer. J Basic Clin Pharm. 2012;3(2):261.
23. Franklin JM, Glynn RJ, Martin D, Schneeweiss S. Evaluating the use of nonrandomized real-world data analyses for regulatory decision making. Clin Pharmacol Ther. 2019;105(4):867–877.
24. Waller P, Mann RD. Pharmacovigilance: principles and database systems. Wiley; 2002.Mann RD. Pharmacovigilance: a practical approach. Wiley; 2007.